biostudies-literatureUnknown18(3)Alexander MIntegration of clinical pharmacogenomics (PGx) within routine cancer care is limited despite frequent use of medicines impacted by PGx, evidence for the benefits of PGx, and the availability of international PGx clinical guidelines. Our study objective was to develop survey tools to assess PGx knowledge, attitudes, practices, perceptions, and education needs among (a) doctors, nurses, and pharmacists involved in cancer care (healthcare professionals, HCPs) and (b) adults who have received cancer treatment or their carers (consumers), with the view to informing implementation strategies for PGx in solid and hematologic cancers. Survey tools were developed in a three-phase (ph) mixed-methods approach. Content was informed by systematic literature review findings and framed by determinants ofClinical and translational sciencee70144https://www.ebi.ac.uk/biostudies/studies/S-EPMC11919918biostudies-literatureInforming Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers.PMC11919918Lingaratnam SKepert AWickens JRoutledge DBozkurt AHarris SGeorgiou CDevine JChen ZYKhot AHird ARowan GWhitechurch AAlexander MLim CXHussainy SYSamo MUnderhill CPergolini MGlewis SLeong LSavas PfalseInforming Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers.Integration of clinical pharmacogenomics (PGx) within routine cancer care is limited despite frequent use of medicines impacted by PGx, evidence for the benefits of PGx, and the availability of international PGx clinical guidelines. Our study objective was to develop survey tools to assess PGx knowledge, attitudes, practices, perceptions, and education needs among (a) doctors, nurses, and pharmacists involved in cancer care (healthcare professionals, HCPs) and (b) adults who have received cancer treatment or their carers (consumers), with the view to informing implementation strategies for PGx in solid and hematologic cancers. Survey tools were developed in a three-phase (ph) mixed-methods approach. Content was informed by systematic literature review findings and framed by determinants of2025-01-01T00:00:00Z2025 Mar2025-04-18T12:51:17.111Z2025-04-06T22:15:37.39ZS-EPMC119199184010327910.1111/cts.70144